Overview

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Status:
Completed

Trial end date:
2017-03-06

Target enrollment:

Participant gender:

Summary

This is a open-label, single ascending dose, pharmacokinetic, and tolerability study of NFC-1 in Children and Adolescents (Ages 6-17 Years) with ADHD.

Phase:

Phase 1

Details

Lead Sponsor:

Aevi Genomic Medicine
Aevi Genomic Medicine, LLC, a Cerecor company